Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: Toward precision medicine

Pharmacogenomics

Volumn 17, Issue 12, 2016, Pages 1365-1378

  Yin, Ji Ye ^a,b,c   Li, Xi ^a,b,c   Zhou, Hong Hao ^a,b,c   Liu, Zhao Qian ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Province Cooperative Innovation Center for Molecular Targeted New Drug Study   (China)

Author keywords

chemotherapy sensitivity; NSCLC; pharmacogenomics; platinum; polymorphism; precision medicine; SNP

Indexed keywords

ABC TRANSPORTER; FOLIC ACID; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM DERIVATIVE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT;

ABCB1 GENE; ACCURACY; APE1 GENE; APOPTOSIS; BAG1 GENE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DNA REPAIR; DRUG RESPONSE; DRUG SENSITIVITY; ERCC1 GENE; ERCC2 GENE; ERCC5 GENE; EXCISION REPAIR; FOLATE METABOLISM; GENETIC VARIATION; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HUMAN; MTHFR GENE; NON SMALL CELL LUNG CANCER; PHARMACOGENOMICS; PREDICTION; REVIEW; RRM1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TYMS GENE; XPA GENE; XRCC1 GENE; XRCC3 GENE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LUNG NEOPLASMS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PLATINUM COMPOUNDS; PRECISION MEDICINE;

EID: 84981187583     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0074     Document Type: Review

References (136)

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115-132 (2016
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002
3. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 526(7573), 343-350 (2015
4. Yin JY, Huang Q, Yang Y, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics 19(3), 206-216 (2009
5. Huang Q, Yang TL, Tang BS, et al. Two novel functional single nucleotide polymorphisms of ADRB3 are associated with Type 2 diabetes in the Chinese population. J. Clin. Endocrinol. Metab. 98(7), E1272-E1277 (2013
6. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7(6), e38150 (2012
7. Chen J, Wang Z, Zou T, et al. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis. Oncotarget doi: 10.18632/oncotarget.9688 (2016) (Epub ahead of print
8. Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 5, e1257 (2014
9. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007
10. Chen S, Huo X, Lin Y, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int. J. Hyg. Environ. Health 213(2), 140-145 (2010
11. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15(8), 1194-1203 (2004
12. Yan PW, Huang XE, Yan F, Xu L, Jiang Y. Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinumbased chemotherapy for advanced non small cell lung cancer. Asian Pac. J. Cancer Prev. 12(9), 2291-2294 (2011
13. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75(4), 380-385 (2008
14. Vinolas N, Provencio M, Reguart N, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71(2), 191-198 (2011
15. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78(1), 49-55 (2009
16. Wei HB, Hu J, Shang LH, et al. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin. Med. J. (Engl.) 125(16), 2902-2907 (2012
17. Wei HB, Lu XS, Shang LH, et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch. Med. Res. 42(5), 412-420 (2011
18. Han B, Gao G, Wu W, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 72(2), 238-243 (2011
19. Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 65(3), 437-446 (2010
20. Muller PJ, Dally H, Klappenecker CN, et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int. J. Cancer 124(7), 1669-1674 (2009
21. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 72(18), 4616-4621 (2012
22. Li XP, Yin JY, Wang Y, et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol. 35(8), 8259-8265 (2014
23. Xu X, Ren H, Zhou B, et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 77(2), 438-442 (2012
24. Wang Y, Yin JY, Li XP, et al. The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS ONE 9(3), e91967 (2014
25. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224(3), 893-899 (1994
26. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys. 366(1), 89-94 (1999
27. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 10(2), 118-123 (2009
28. Lv H, Han T, Shi X, et al. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med. Oncol. 31(8), 86 (2014
29. Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 118(9), 2466-2475 (2012
30. Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and nonsmall cell lung cancer. J. Thorac. Oncol. 1(7), 679-683 (2006
31. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med. Wkly 141, w13275 (2011
32. Ada AO, S CK, Hancer F, et al. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma 57(6), 512-521 (2010
33. Yang Y, Xian L. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. Tumour Biol. 35(7), 6791-6799 (2014
34. Li W, Yue W, Zhang L, et al. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 190(1), 91-98 (2012
35. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85 (2004
36. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006
37. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3), 555-560 (2000
38. Li F, Sun X, Sun N, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 33(5), 489-494 (2010
39. Metro G, Chiari R, Mare M, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother. Pharmacol 68(6), 1405-1412 (2011
40. Li D, Zhou Q, Liu Y, Yang Y, Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med. Oncol. 29(3), 1622-1628 (2012
41. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67(1), 101-107 (2010
42. Tiseo M, Bordi P, Bortesi B, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br. J. Cancer 108(8), 1695-1703 (2013
43. Kalikaki A, Voutsina A, Koutsopoulos A, et al. ERCC1 SNPs as potential predictive biomarkers in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Invest. 33(4), 107-113 (2015
44. Liao WY, Shih JY, Chang GC, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall-cell lung cancer patients treated with gemcitabine/platinum. J. Thorac. Oncol. 7(6), 973-981 (2012
45. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56(2), 281-288 (2007
46. Sullivan I, Salazar J, Majem M, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 353(2), 160-166 (2014
47. Mazzoni F, Cecere FL, Meoni G, et al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer 82(2), 288-293 (2013
48. Zhao X, Zhang Z, Yuan Y, Yuan X. Polymorphisms in ERCC1 gene could predict clinical outcome of platinumbased chemotherapy for non-small cell lung cancer patients. Tumour Biol. 35(8), 8335-8341 (2014
49. Krawczyk P, Kucharczyk T, Kowalski DM, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J. Cancer Res. Clin. Oncol. 140(12), 2047-2057 (2014
50. Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer-a pilot study. Folia Histochem. Cytobiol. 50(1), 80-86 (2012
51. Huang SJ, Wang YF, Jin ZY, Sun JY, Guo ZL. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour Biol. 35(5), 4023-4029 (2014
52. Hong W, Wang K, Zhang YP, et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabinebased chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J. Zhejiang Univ. Sci. B 14(3), 207-215 (2013
53. Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinumbased chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 35(4), 2905-2921 (2014
54. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 526(2), 265-274 (2013
55. Yin M, Yan J, Voutsina A, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 72(3), 370-377 (2011
56. Huang D, Zhou Y. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a metaanalysis based on 44 studies. Biomed. Rep. 2(4), 452-462 (2014
57. Yu D, Shi J, Sun T, et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol 33(3), 877-884 (2012
58. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28(1), 315-321 (2011
59. Kimcurran V, Zhou C, Schmid-Bindert G, et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv. Med. Sci. 56(1), 30-38 (2011
60. Moller P, Wallin H, Dybdahl M, Frentz G, Nexo BA. Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma. Cancer Lett. 151(2), 187-192 (2000
61. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23(2), 295-299 (2002
62. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet. Genomics 17(11), 897-905 (2007
63. Yao CY, Huang XE, Li C, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinumbased chemotherapy for advanced non small cell lung cancers. Asian Pac. J. Cancer Prev. 10(5), 859-864 (2009
64. Li P, Wang YD, Cheng J, Chen JC, Ha MW. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen. Tumour Biol. 36(12), 9465-9473 (2015
65. Shiraishi K, Kohno T, Tanai C, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 28(33), 4945-4952 (2010
66. Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y, Wan HY. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatingemcitabine. Genet. Mol. Res. 13(2), 3310-3318 (2014
67. Kim SH, Lee GW, Lee MJ, et al. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Lung Cancer 77(3), 578-584 (2012
68. Li XD, Han JC, Zhang YJ, Li HB, Wu XY. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac. J. Cancer Prev. 14(1), 145-148 (2013
69. Wu W, Li H, Wang H, et al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS ONE 7(3), e33200 (2012
70. Zhang L, Ma W, Li Y, Wu J, Shi GY. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genet. Mol. Res. 13(1), 228-236 (2014
71. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin. Cancer Res. 13(10), 2876-2881 (2007
72. Provencio M, Camps C, Cobo M, et al. Prospective assessment of XRCC3, XPD and Aurora kinase A singlenucleotide polymorphisms in advanced lung cancer. Cancer Chemother. Pharmacol. 70(6), 883-890 (2012
73. Qin Q, Zhang C, Yang X, et al. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PLoS ONE 8(11), e79864 (2013
74. Qiu M, Yang X, Hu J, et al. Predictive value of XPD polymorphisms on platinum-based chemotherapy in nonsmall cell lung cancer: a systematic review and meta-analysis. PLoS ONE 8(8), e72251 (2013
75. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65(2), 230-236 (2009
76. Liu D, Wu J, Shi GY, Zhou HF, Yu Y. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Genet. Mol. Res. 13(2), 3100-3107 (2014
77. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet. Mol. Res. 13(3), 7617-7625 (2014
78. He C, Duan Z, Li P, Xu Q, Yuan Y. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs 24(3), 300-305 (2013
79. Zhang T, Sun J, Lv M, et al. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. Asian Pac. J. Cancer Prev. 14(2), 701-705 (2013
80. Feng J, Sun X, Sun N, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim. Biophys. Sin. (Shanghai) 41(5), 429-435 (2009
81. Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47(2), 183-192 (2005
82. Zhu XL, Sun XC, Chen BA, et al. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer. Chin. Med. J. (Engl) 123(23), 3427-3432 (2010
83. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu. Rev. Genet. 38 445-476 (2004
84. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2(8), 901-908 (2003
85. Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25(5), 757-763 (2004
86. Peng Y, Li Z, Zhang S, et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int. J. Cancer 135(11), 2687-2696 (2014
87. Zhao W, Hu L, Xu J, et al. Polymorphisms in the base excision repair pathway modulate prognosis of platinumbased chemotherapy in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 71(5), 1287-1295 (2013
88. Li L, Wan C, Wen FQ. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis. Genet. Mol. Res. 13(2), 3772-3786 (2014
89. Wu J, Liu J, Zhou Y, et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin. Cancer Res. 18(14), 3972-3981 (2012
90. Chen J, Zhao QW, Shi GM, Wang LR. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J. Zhejiang Univ. Sci. B 13(11), 875-883 (2012
91. Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin. Cell. Dev. Biol. 22(8), 898-905 (2011
92. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9), 1437-1445 (2001
93. Zhou C, Ren S, Zhou S, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J. Clin. Oncol. 40(10), 954-960 (2010
94. Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J. Thorac. Oncol. 6(12), 2018-2026 (2011
95. Qiu M, Xu L, Yang X, et al. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer. PLoS ONE 8(10), e77005 (2013
96. Shen XY, Lu FZ, Wu Y, Zhao LT, Lin ZF. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PLoS ONE 8(8), e69553 (2013
97. Jiang YH, Xu XL, Ruan HH, et al. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer. Med. Oncol. 31(5), 959 (2014
98. Xu JL, Hu LM, Huang MD, et al. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Asian Pac. J. Cancer Prev. 13(3), 851-856 (2012
99. Cheng H, Sun N, Sun X, et al. Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim. Biophys. Sin. (Shanghai) 42(5), 311-317 (2010
100. Yin JY, Dong Z, Liu ZQ, Zhang JT. Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. Biosci. Rep. 31(1), 1-15 (2011
101. Yin JY, Dong ZZ, Liu RY, Chen J, Liu ZQ, Zhang JT. Translational regulation of RPA2 via internal ribosomal entry site and by eIF3a. Carcinogenesis 34(6), 1224-1231 (2013
102. Yin JY, Shen J, Dong ZZ, et al. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin. Cancer Res. 17(13), 4600-4609 (2011
103. Yin JY, Meng XG, Qian CY, et al. Association of positively selected eIF3a polymorphisms with toxicity of platinumbased chemotherapy in NSCLC patients. Acta Pharmacol. Sin. 36(3), 375-384 (2015
104. Xu X, Han L, Duan L, et al. Association between eIF3alpha polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients. Br. J. Clin. Pharmacol. 75(2), 516-523 (2013
105. Xu X, Han L, Yang H, et al. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients. Lung Cancer 79(1), 65-72 (2013
106. Gu S, Wu Q, Zhao X, et al. Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci. 103(8), 1451-1459 (2012
107. Peng Y, Wang L, Qing Y, et al. Polymorphisms of BCL2 and BAX genes associate with outcomes in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Sci Rep 5 17766 (2015
108. Qian J, Gu S, Wu Q, et al. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. Chest 142(3), 680-689 (2012
109. Wang YD, Ha MW, Cheng J, et al. The role of expression and polymorphism of the BAG-1 gene in response to platinumbased chemotherapeutics in NSCLC. Oncol. Rep. 27(4), 979-986 (2012
110. Wu F, Zhang J, Liu Y, Zheng Y, Hu N. HIF1alpha genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol. Biochem. 32(6), 1566-1576 (2013
111. Fang HM, Tian G, Zhou LJ, Zhou HY, Fang YZ. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer. Acta Pharmacol Sin 34(4), 549-554 (2013
112. Wu F, Hu N, Li Y, Bian B, Xu G, Zheng Y. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol. (Dordr) 35(3), 175-180 (2012
113. Zhao X, Wang X, Wu W, et al. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinumbased chemotherapy. Cancer 118(14), 3587-3598 (2012
114. Liu L, Zhou F, Ren S, et al. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with firstline platinum-based chemotherapy. Asia Pac. J. Clin. Oncol. doi: 10.1111/ajco.12258 (2014) (Epub ahead of print
115. Chen J, Yin JY, Li XP, et al. Association of Wnt-inducible signaling pathway protein 1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Clin. Lung. Cancer. doi: 10.1016/j.cllc.2014.12.008 (2014) (Epub ahead of print
116. Li X, Shao M, Wang S, et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol. 35(11), 11159-11170 (2014
117. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS. Influence of polymorphisms in MTHFR 677 C->T, TYMS 3R->2R and MTR 2756 A->G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 12(6), 797-808 (2011
118. Zhu N, Gong Y, He J, Xia J, Chen X. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis. Yonsei Med. J. 54(6), 1384-1393 (2013
119. Kucharczyk T, Krawczyk P, Powrozek T, et al. The Effectiveness of pemetrexed monotherapy depending on polymorphisms in TS and MTHFR genes as well as clinical factors in advanced NSCLC Patients. Pathol. Oncol. Res. 22(1), 49-56 (2016
120. Maring JG, Groen HJ, Wachters FM, Uges DR, De Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5(4), 226-243 (2005
121. Lima A, Azevedo R, Sousa H, Seabra V, Medeiros R. Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics. Pharmacogenomics 14(11), 1337-1351 (2013
122. Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol. Lett. 5(4), 1165-1170 (2013
123. Hu Q, Li X, Su C, et al. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp. Ther. Med. 4(6), 1010-1016 (2012
124. Smit EF, Burgers SA, Biesma B, et al. Randomized Phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 27(12), 2038-2045 (2009
125. Liu L, Wu J, Zhong R, et al. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinumbased chemotherapy in non-small-cell lung cancer. Mol. Carcinog. 52(12), 923-931 (2013
126. Yin JY, Li X, Li XP, et al. Prediction models for platinumbased chemotherapy response and toxicity in advanced NSCLC patients. Cancer Lett. 377(1), 65-73 (2016
127. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B.∗1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011
128. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81(3), 427-437 (2007
129. Wheeler HE, Gamazon ER, Stark AL, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 13(1), 35-43 (2013
130. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452(7187), 638-642 (2008
131. Xu H, Robinson GW, Huang J, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat. Genet. 47(3), 263-266 (2015
132. Tan BR, Thomas F, Myerson RJ, et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 29(7), 875-883 (2011
133. Li X, Liu R, Yan H, et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J. Clin. Pharmacol. doi: 10.1002/jcph.392 (2014) (Epub ahead of print
134. Patch AM, Christie EL, Etemadmoghadam D, et al. Wholegenome characterization of chemoresistant ovarian cancer. Nature 521(7553), 489-494 (2015
135. Gong WJ, Yin JY, Li XP, et al. Association of wellcharacterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol. doi: 10.1007/s13277-015-4497-5 (2016) (Epub ahead of print
136. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404), 532-536 (2012